Breakthrough study finds single dose of psychedelics significantly reduced depression symptoms in clinical trial, with effects lasting up to six months.
A single dose of the psychedelic drug dimethyltryptamine (DMT), given with psychological support, rapidly reduced depressive symptoms in 34 adults with major depressive disorder, according to a ...
A single dose of psychedelics significantly reduced symptoms in people with major depressive disorder, a new study found. The clinical trial was led by researchers at Imperial College London, where the team found that participants with depression who took the psychedelic dimethyl…
A psychedelic drug known for its intense but short‑lived effects has shown rapid relief for people with major depression, according to a new clinical trial.
Methods In this double-blind, randomised clinical trial, 52 participants diagnosed with major depressive disorder and no unstable somatic conditions were allocated to receive either a single, moderate dose (0.215 mg/kg body weight) of psilocybin or placebo in conjunction with psy…
A single dose of psilocybin eased symptoms of depression within days, with benefits lasting for more than three months compared to placebo, our new study has found.
A new Swedish trial gave 35 depressed patients one dose of psilocybin. Half were in remission six weeks later. Here's what the study found, and where the benefit ran out.
Importance: Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective: To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD.
Summary: A Phase 2 randomized clinical trial demonstrates that a single 25 mg dose of psilocybin, combined with psychotherapeutic support, provides rapid, statistically significant, and clinically meaningful reduction in symptoms of common, recurrent depression. The study showed…